Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1347-1349

  Hitt, R ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Advanced head and neck cancer; Cisplatin; Gemcitabine; Phase II trial

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; BONE MARROW DISEASES; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0032441793     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008413818569     Document Type: Article

References (12)

1. Schantz SP, Harrison LB, Forasterie AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharinx. In De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia, PA: Lippincott-Raven 1997; 741-801.
2. Pinto HA, Jacobs CJ. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol/Oncol Clin North Am 1991; 5: 667-86.
3. Plunket W, Huang P, Searcy C, Gandhi V. Gemcitabine: Pre-clinical, pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl 10): 3-15.
4. Hertel LW, Boder OB, Kroin JS et al. Evaluation of thr antitumor activity of gemcitabine (2′2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
5. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (Ly 188011) in patients with advanced squamous-cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
6. Crinó L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine conbinatoin in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
7. Castellano D, Lianes P, Paz-Ares L, Hidalgo M et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 1998; 9: 457-9.
8. Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In De Vita VTJ, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA: Lippincott 1988; 121-41.
9. Simon R. Optimal two-stages designs for phase II clinical trials. Control ClinTrials 1989; 10: 1-10.
10. Forastiere AA, Metch B, Schuller D et al. Randomized comparison of cisplatin and 5-fluorouracil versus carboplatin + 5-FU versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992; 10:1245.
11. Jacobs C, Lyman G, Velez-García et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous-cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257.
12. Peters GJ, Bergman AM, Ruiz van Haperen VWet al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (Suppl 11): 72-9.